Jesse Elliott1, Shannon E Kelly1, Amy Johnston1, Becky Skidmore1, Tara Gomes1, George A Wells1. 1. Affiliations: School of Epidemiology, Public Health and Preventive Medicine (Elliott, Kelly, Wells), University of Ottawa; Cardiovascular Research Methods Centre (Elliott, Kelly, Johnston, Wells), University of Ottawa Heart Institute; Li Ka Shing Knowledge Institute (Gomes), St. Michael's Hospital, Toronto, Ont. Becky Skidmore is an independent contractor in Ottawa, Ont.
Abstract
BACKGROUND: Allergic rhinitis and asthma are important public health concerns, yet there is no consensus about the benefits and harms of allergen-specific immunotherapy to treat these conditions. We performed an umbrella review of systematic reviews summarizing the current evidence for the benefits and harms of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). METHODS: We searched MEDLINE, Embase, the Cochrane Library and the grey literature from Jan. 1, 2010 to Nov. 20, 2016 for systematic reviews of randomized controlled trials or prospectively controlled studies involving children or adults with allergic rhinitis or asthma. Outcomes were summarized narratively (benefits: total combined symptom-medication score, symptom score, medication score, disease-specific quality of life, adherence; harms: anaphylaxis, death, local and systemic reactions). RESULTS: Twenty-three systematic reviews were included. SCIT and SLIT were more effective than placebo for most outcomes. SCIT was better than SLIT at improving medication and symptom scores, with no differences in quality of life; however, data were limited for this comparison. Anaphylaxis and death were infrequently reported. Few reviews assessed benefits or harms among children. INTERPRETATION: Allergen immunotherapy appears to be effective among patients with allergic rhinitis and asthma. The safety of allergen immunotherapy is not conclusively established, although death and anaphylaxis appear to be rare. PROSPERO no.: CRD42015024590. Copyright 2017, Joule Inc. or its licensors.
BACKGROUND:Allergic rhinitis and asthma are important public health concerns, yet there is no consensus about the benefits and harms of allergen-specific immunotherapy to treat these conditions. We performed an umbrella review of systematic reviews summarizing the current evidence for the benefits and harms of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). METHODS: We searched MEDLINE, Embase, the Cochrane Library and the grey literature from Jan. 1, 2010 to Nov. 20, 2016 for systematic reviews of randomized controlled trials or prospectively controlled studies involving children or adults with allergic rhinitis or asthma. Outcomes were summarized narratively (benefits: total combined symptom-medication score, symptom score, medication score, disease-specific quality of life, adherence; harms: anaphylaxis, death, local and systemic reactions). RESULTS: Twenty-three systematic reviews were included. SCIT and SLIT were more effective than placebo for most outcomes. SCIT was better than SLIT at improving medication and symptom scores, with no differences in quality of life; however, data were limited for this comparison. Anaphylaxis and death were infrequently reported. Few reviews assessed benefits or harms among children. INTERPRETATION: Allergen immunotherapy appears to be effective among patients with allergic rhinitis and asthma. The safety of allergen immunotherapy is not conclusively established, although death and anaphylaxis appear to be rare. PROSPERO no.: CRD42015024590. Copyright 2017, Joule Inc. or its licensors.
Authors: Philippe J Bousquet; Moisés A Calderón; Pascal Demoly; Désirée Larenas; Giovanni Passalacqua; Claus Bachert; Jan Brozek; G Walter Canonica; Thomas Casale; Joao Fonseca; Ronald Dahl; Stephen R Durham; Hans Merk; Margitta Worm; Ulrich Wahn; Torsten Zuberbier; Holger J Schünemann; Jean Bousquet Journal: J Allergy Clin Immunol Date: 2010-11-26 Impact factor: 10.793
Authors: Kaveh G Shojania; Margaret Sampson; Mohammed T Ansari; Jun Ji; Steve Doucette; David Moher Journal: Ann Intern Med Date: 2007-07-16 Impact factor: 25.391
Authors: Danilo Di Bona; Antonella Plaia; Maria Stefania Leto-Barone; Simona La Piana; Gabriele Di Lorenzo Journal: JAMA Intern Med Date: 2015-08 Impact factor: 21.873
Authors: Michael D Seidman; Richard K Gurgel; Sandra Y Lin; Seth R Schwartz; Fuad M Baroody; James R Bonner; Douglas E Dawson; Mark S Dykewicz; Jesse M Hackell; Joseph K Han; Stacey L Ishman; Helene J Krouse; Sonya Malekzadeh; James Whit W Mims; Folashade S Omole; William D Reddy; Dana V Wallace; Sandra A Walsh; Barbara E Warren; Meghan N Wilson; Lorraine C Nnacheta Journal: Otolaryngol Head Neck Surg Date: 2015-02 Impact factor: 3.497
Authors: Peter S Creticos; David I Bernstein; Thomas B Casale; Richard F Lockey; Jennifer Maloney; Hendrik Nolte Journal: J Allergy Clin Immunol Pract Date: 2016-06-24
Authors: A Meadows; B Kaambwa; N Novielli; A Huissoon; A Fry-Smith; C Meads; P Barton; J Dretzke Journal: Health Technol Assess Date: 2013-07 Impact factor: 4.014
Authors: Beverley J Shea; Jeremy M Grimshaw; George A Wells; Maarten Boers; Neil Andersson; Candyce Hamel; Ashley C Porter; Peter Tugwell; David Moher; Lex M Bouter Journal: BMC Med Res Methodol Date: 2007-02-15 Impact factor: 4.615
Authors: Mohamed S Al-Moamary; Sami A Alhaider; Abdullah A Alangari; Mohammed O Al Ghobain; Mohammed O Zeitouni; Majdy M Idrees; Abdullah F Alanazi; Adel S Al-Harbi; Abdullah A Yousef; Hassan S Alorainy; Mohamed S Al-Hajjaj Journal: Ann Thorac Med Date: 2019 Jan-Mar Impact factor: 2.219